Antiestrogenic therapy in breast cancer and endometrial modifications

The aim of this retrospective study was to detect endometrial lesions in tamoxifen breast cancer users (menopausal state related). The meaning of genital bleeding during the treatment and the actual incidence of benign and malignant pathology of the endometrium related to length of treatment was also evaluated. Tamoxifen (TMX) is a nonsteroidal triphenylene derivate with clear antiestrogenic properties on the breast which is used as adjuvant treatment for breast cancer; potential adverse effects include endometrial lesions. Three hundred and sixty-six breast cancer patients were enrolled in this study; 292 patients were treated with 20 mg/daily of TMX as adjuvant therapy and the remaining 74 did not receive therapy. All patients were subdivided in premenopausal and postmenopausal, asymptomatic and symptomatic groups. All patients underwent ultrasound scans (to examine endometrial thickness) and hysteroscopic examinations before treatment and after one, three and five years. Endometrial biopsy under direct hysteroscopic vision was systematically performed. The pathological histology reports were classified under polyps, simple hyperplasia, complex hyperplasia, atypical hyperplasia, and carcinoma. A higher incidence of endometrial pathology was found only in symptomatic postmenopausal TMX treated patients (27.2% vs 19.5%) between the third and fifth year of treatment.

Tamoxifen; Endometrial pathology; Breast cancer

[1] Robbins: "Le basi patologiche delle malattie". Piccin Editore. Edizione VI, 2000, 1, 319.

[2] Touraine Ph., Driguez P., Cartier I., Yaneva H., Kuttenn F., Mauvais-Jarvis: "Lack of induction of endometrial hyperplasia with Tamoxifen". Lancet, 1995, 345, 254.

[3] Anderson E., Howell A.: "The molecular biology of endocrine responsiveness in breast cancer". In: Yarnold J.R., Stratton M., McMillan T.J. (eds.), "Molecular Biology for Oncologists", London, Chapman & Hall, 1996, 217.

[4] Bartlett K., Eremin O., Hutcheon A., Preece P., Scott J.S., Forrest P. et al.: "Breast Cancer Trials Committee. Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer. The Scottish trials". Lancet, 1987, 2, 171.

[5] Fisher B., Costantino J., Redmond L., Poisson R., Bowman D., Couture J. et al.: "A randomized, clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors". N. Engl. J. Med., 1989, 320, 479.

[6] Buchanan R.B., Blarney R.W., Durrent K.R., Howel A., Paterson A.G., Preece P.E. et al.: "A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer". J. Clin. Oncol., 1986, 4, 1326.

[7] American College of Obstetrician and Gynecologists: "Tamoxifen and endometrial cancer". ACOG Committee Opinion No. 169, Washington, DC, American College of Obstetricians and Gynecologists, 1996.

[8] Love R.R.: "Tamoxifen prophylaxis in breast cancer". Oncology, 1992, 6, 33.

[9] Varras M., Polyzos D., Akrivis Ch.: "Effects of tamoxifen on the human female genital tract: review of the literature". Eur. J. Gynaecol. Oncol., 2003, 24, 258.

[10] De Muylder X., Neven P., de Somer M., Van Belle Y., Vanderck G., De Muylder E.: "Endometrial lesions in patients undergoing tamoxifen therapy". Int. J. Gynecol. Obstet., 1991, 36, 127.

[11] Ismail S.M.: "Pathology of endometrium treated with tamoxifen". J. Clin. Pathol., 1994, 47, 827.

[12] Pomander T., Rutquist L.E., Cedamark B., Mattson A., Skoog L., Theve T.: "Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers"._Lancet, 1994, 343, 448.

[13] van Leeuwen F.E., Benraadt J., Coebergh J.W., Kiemeney L.A., Gimbrere Otter R., Schouten L.J. et al.: "Risk of endometrial cancer after tamoxifen treatment of breast cancer". Lancet, 1994, 343, 448.

[14] Hoover R.,F raumeni J.F.,E verson R. et al.: "Cancer of the uterine corpus after ormonal treatment for breast cancer". Lancet, 1976, 1, 885.

[15] Friedl A., Jordan V.C.: "W hat do we know and what don't we know about tamoxifen in the human uterus". Breast Cancer Res. Treat., 1994, 31, 27.

[16] Breast Cancer Trials Committee, Scottish Cancer Trials Office: "Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial". Lancet, 1987, 2, 171.

[17] Katase K., Sugiyama Y., Hasumi K., Yoshimoto M., Kasumi F.: "The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma". Cancer, 1997, 82, 1698.

[18] Taponeco F., Curcio C., Fasciani A., Artini P.G., Fornaciari G., Petraglia F., Genazzani A.R.: "Indication of hysteroscopy in tamoxifen treated breast cancer patients". J. Exp. Clin. Cancer Res., 2002, 21, 37.